Translation: Original published in Finnish on 5/25/2026 at 7:15 am EEST.

Nightingale Health announced on Friday that it has signed a memorandum of understanding with Formula 100 Health to integrate its blood analysis technology into the latter's longevity programs in Switzerland and South Africa. As this is an MOU and we expect initial volumes to be modest, the news will not result in any immediate changes to our forecasts.

New foray into preventive healthcare's longevity segment

Per the memorandum of understanding, Nightingale Health Check will be integrated into the lifestyle and nutrition programs offered by the Formula 100 Health network. The partnership will launch as early as this summer in Zurich, Switzerland, with plans to expand to South Africa at a later date. Formula 100 Health partners with clinics, hotels, retirement homes, and other services. We view this target group (the "longevity" segment, which focuses on maximizing healthy years of life) as a natural fit for Nightingale's technology because the company's data on disease risks directly addresses the needs of preventive healthcare and lifestyle change assessment.

Economic potential will depend on scaling volumes

Although we view this news as an encouraging sign of international interest in Nightingale’s technology, we remain cautious about announcements at the memorandum of understanding stage. As we have previously emphasized, for Nightingale’s business model to become profitable, revenue must multiply and significant sample volumes must be analyzed. As far as we understand, the commercial details of the now-announced partnership are still being worked out, and the commercial ramp-up of new customer relationships typically takes time. We are closely monitoring the progress of this collaboration as it moves toward a binding agreement, particularly how quickly the Formula 100 Health network can generate concrete, consistent sample volumes for Nightingale.